---
title: "Plasma Fractionation Market: Growing at a CAGR of 7.1%"
datePublished: Thu Jul 27 2023 09:16:39 GMT+0000 (Coordinated Universal Time)
cuid: clkkxxcrb00030ameba0ocda1
slug: plasma-fractionation-market-growing-at-a-cagr-of-71
ogImage: https://cdn.hashnode.com/res/hashnode/image/upload/v1690449374664/54043080-a927-4bdf-b993-2e5c19800046.png
tags: news, business, health-cjaeh844x02vvo3wtj5r2s75q, healthcare

---

Plasma Fractionation Market Size, Share & COVID-19 Impact Analysis, By Product (Albumin, Immunoglobulin (Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)), Coagulation Factors (Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others), Protease Inhibitors, Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, Others), By End-user (Hospitals & Clinics, Clinical Research Laboratories, Others), and Regional Forecast To 2029

Plasma fractionation is the process of separating the different components of blood plasma. The different components of plasma can be used to treat a variety of medical conditions, including haemophilia, immunodeficiency, and burns.

The plasma fractionation market is growing at a CAGR of 7.1%, driven by the increasing demand for blood products, the rising prevalence of chronic diseases, and the technological advancements in plasma fractionation.

**Get More Insights:**Â [https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614](https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614)

**Segmentation**

The plasma fractionation market is segmented by product, application, and region.

The product segment is further segmented into albumin, immunoglobulins, coagulation factors, and others. Albumin is the most common product in the plasma fractionation market, and it is used to treat a variety of medical conditions, including hypovolemia, shock, and burns. Immunoglobulins are used to treat immunodeficiency disorders, and coagulation factors are used to treat haemophilia.

The application segment is further segmented into therapeutic and diagnostic. The therapeutic segment is the largest, and it is driven by the increasing demand for blood products to treat a variety of medical conditions. The diagnostic segment is the smaller segment, and it is driven by the increasing demand for plasma-derived products to diagnose diseases.

The region segment is further segmented into North America, Europe, Asia-Pacific, and Latin America. North America is the largest market for plasma fractionation, due to the high prevalence of chronic diseases and the early adoption of new technologies.

**Key Players**

The key players in the plasma fractionation market include Grifols, Kedrion, CSL Behring, Octapharma, and Biotest. These companies are investing in research and development to develop new and innovative plasma fractionation technologies.

**Trends**

The plasma fractionation market is expected to continue to grow in the coming years, driven by the following trends:

* Increasing demand for blood products: The global demand for blood products is expected to increase in the coming years, due to the increasing prevalence of chronic diseases and the ageing population.
    
* Rising prevalence of chronic diseases: The prevalence of chronic diseases, such as haemophilia and immunodeficiency, is increasing in the world. This is driving the demand for plasma-derived products to treat these diseases.
    
* Technological advancements: There have been significant technological advancements in plasma fractionation in recent years. These advancements have made plasma fractionation more efficient and safer.
    

**Conclusion**

The plasma fractionation market is a growing market, and it is expected to continue to grow in the coming years. The market is being driven by the increasing demand for blood products, the rising prevalence of chronic diseases, and the technological advancements in plasma fractionation.